Why Retatrutide Was Studied Once Weekly: Half-Life and Trial Design
A long half-life helped researchers evaluate weekly administration. Pharmacokinetics alone cannot establish an approved schedule or instructions for missed doses.
FormBlends Editorial Research · Updated 2026-09-27
What half-life means
Half-life describes the time associated with a decline in drug concentration during an elimination phase. In the phase 1b study reported by Urva and colleagues in The Lancet, retatrutide had a half-life of approximately six days. That finding helped support the investigation of once-weekly administration.
A design choice in particular trials
The phase 2 obesity study used once-weekly administration with randomized target-dose and starting-dose groups. Earlier development also included single-dose research, so it is inaccurate to describe every retatrutide experiment as a weekly treatment trial. Frequency, formulation and follow-up belong to the specific study being discussed.
What a concentration model cannot tell us
A simplified exposure curve cannot establish how symptoms will change on different days or whether another interval improves tolerability. Nor can a long half-life supply a safe missed-dose window, injection-day change rule or split-dose plan. Those are clinical questions requiring direct evidence and, for an approved product, validated prescribing information.
Research boundaries
Retatrutide has no FDA-approved dosing instructions and cannot be used in compounding under federal law. FormBlends does not offer it. Study participants should obtain protocol instructions from their study team. TRIUMPH-1 is NCT05929066; NCT05882045 identifies TRIUMPH-3.